Further utilizing a technology portfolio it acquired last year, Miraculins will begin validating biomarkers that it hopes cold be used to diagnose pancreatic and stomach cancer, the company announced recently.
Miraculins acquired the biomarkers — along with biomarkers for colorectal and breast cancer — in May 2005 as part of its purchase of Europroteome [See
PM 06/15/06].
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
